Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 04, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jan. 01, 2020	Dec. 31, 2019	Nov. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	95,000,000	95,000,000	95,000,000		95,000,000
Common Stock, Increase in authorized shares (in shares)	35,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001			$ 0.0001
Common Stock, Shares, Issued		60,883,303	60,883,303		60,883,303			47,004,764
Common Stock, Shares, Outstanding		60,883,303	60,883,303		60,883,303			47,004,764
Shelf Registration Statement, Maximum Authorized Securities									$ 100,000,000
Net proceeds of commissions and other transaction costs			$ 5,813,000	$ 3,341,000	$ 8,417,000	$ 7,709,000
Issuance of common shares - Founders Agreement			731,000	92,000	797,000	198,000
Shelf registration statement remaining authorized securities		$ 12,300,000	12,300,000		12,300,000
Amount received for issuance of common stock upon exercise of warrants				$ 0	13,000	$ 0
Non-vested Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested		$ 3,500,000	$ 3,500,000		$ 3,500,000
Weighted average period (in years)					2 years
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding non-vested		333,334	333,334		333,334
Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of outstanding stock options vested and exercisable		0	0		0
2015 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance Authorized		9,000,000	9,000,000		9,000,000
Plans expires (in years)			10 years
Shares are available for issuance		4,298,465	4,298,465		4,298,465
Common Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale price per share		$ 2.40	$ 2.40		$ 2.40
Stock Issued During Period Shares Common Shares For At The Market Offering			2,311,062	1,142,298	3,614,344	2,230,524
Stock Issued During Period Value Common Shares For At The Market Offering Gross					$ 8,700,000
Net proceeds of commissions and other transaction costs			$ 0	$ 0	0	$ 0
Issuance of common shares - Founders Agreement			$ 0	$ 0	$ 0	$ 0
Issuance of stock upon exercise of warrants				26,146	102,742	73,525
Amount received for issuance of common stock upon exercise of warrants				$ 0	$ 0	$ 0
Underwritten Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares sold		7,321,429			7,321,429
Sale price per share		$ 2.80	$ 2.80		$ 2.80
Gross proceeds from issue of shares		$ 20,500,000			$ 20,500,000
Net proceeds from the offering		18,900,000			18,900,000
Underwriting discounts and offering expenses		$ 1,600,000			$ 1,600,000
Fortress Biotech, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares sold	1,459,305				273,379
Percentage of annual equity fee		2.50%	2.50%		2.50%		2.50%
Issuance of common shares - Founders Agreement			$ 797,000		$ 797,000
Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Commission rate		3.00%	3.00%		3.00%
Common Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	7,000,000
Common Stock, Shares, Issued		7,000,000	7,000,000		7,000,000